TRAW Quote, Financials, Valuation and Earnings

Ikena Oncology has a net margin of -14868.42% compared to Traws Pharma's net margin of --. Traws Pharma's return on equity of -124.39% beat Ikena Oncology's return on equity of --.

Traws Pharma has a consensus price target of --, signalling upside risk potential of 150%. On the other hand Ikena Oncology has an analysts' consensus of $3.00 which suggests that it could grow by 127.27%. Given that Traws Pharma has higher upside potential than Ikena Oncology, analysts believe Traws Pharma is more attractive than Ikena Oncology.

Traws Pharma has a beta of 1.422, which suggesting that the stock is 42.177% more volatile than S&P 500. In comparison Ikena Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ikena Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. Ikena Oncology pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are larger than Ikena Oncology quarterly revenues of --. Traws Pharma's net income of -$8.5M is higher than Ikena Oncology's net income of -$9.1M. Notably, Traws Pharma's price-to-earnings ratio is -- while Ikena Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 9.71x versus 6.95x for Ikena Oncology. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -14868.42% compared to Traws Pharma's net margin of -49.65%. Traws Pharma's return on equity of -124.39% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Traws Pharma has a consensus price target of --, signalling upside risk potential of 150%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 39.8%. Given that Traws Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe Traws Pharma is more attractive than NovaBay Pharmaceuticals.

Traws Pharma has a beta of 1.422, which suggesting that the stock is 42.177% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.363%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Traws Pharma's net income of -$8.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Traws Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 9.71x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -14868.42% compared to Traws Pharma's net margin of -2357.27%. Traws Pharma's return on equity of -124.39% beat Palatin Technologies's return on equity of --.

Traws Pharma has a consensus price target of --, signalling upside risk potential of 150%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 957.24%. Given that Palatin Technologies has higher upside potential than Traws Pharma, analysts believe Palatin Technologies is more attractive than Traws Pharma.

Traws Pharma has a beta of 1.422, which suggesting that the stock is 42.177% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are smaller than Palatin Technologies quarterly revenues of $350K. Traws Pharma's net income of -$8.5M is lower than Palatin Technologies's net income of -$2.4M. Notably, Traws Pharma's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 9.71x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -14868.42% compared to Traws Pharma's net margin of --. Traws Pharma's return on equity of -124.39% beat Theriva Biologics's return on equity of --.

Traws Pharma has a consensus price target of --, signalling upside risk potential of 150%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 426.32%. Given that Theriva Biologics has higher upside potential than Traws Pharma, analysts believe Theriva Biologics is more attractive than Traws Pharma.

Traws Pharma has a beta of 1.422, which suggesting that the stock is 42.177% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are larger than Theriva Biologics quarterly revenues of --. Traws Pharma's net income of -$8.5M is lower than Theriva Biologics's net income of -$4.4M. Notably, Traws Pharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 9.71x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.